Search

Prostate cancer (PCa) is one of the leading diseases in men all over the world caused due to over-expression of prostate-specific membrane antigen (PSMA). Currently, the detection and targeting of PCa is one of the major challenges in the prostate gland. Therefore, Bruton tyrosine kinase inhibitor molecules like ibrutinib (Ibr) loaded with nanomaterials like multiwalled carbon nanotubes (MWCNTs), which has good physico-chemical properties may be the best regimen to treat PCa. In this strategy, the chemically modified MWCNTs have excellent 'Biosensing' properties makes it easy for detecting PCa without fluorescent agent and thus targets particular site of PCa. In the present study, Ibr/MWCNTs conjugated with T30 oligonucleotide may selectively target and inhibit PSMA thereby reduce the over-expression in PCa. Hence, the proposed formulation design can extensively reduce the dosage regimen without any toxic effect. Additionally, the present hypothesis also revealed the binding mode of Ibr in the catalytic pocket of PSMA by in silico method. Therefore, we presume that if this hypothesis proves correct, it becomes an additional novel tool and one of the conceivable therapeutic options in treating PCa. [ABSTRACT FROM AUTHOR]

In the digital age, cybercrime is spreading its root widely. Internet evolution has turned out to a boon as well as curse for those confronting the issues of privacy, national security, social decency, IP rights, child protection, fighting, detecting, and prosecuting cybercrime. Hence, there arises a need to detect the cybercriminal. Cybercrime identification utilizes dataset that is taken from CBS open dataset. For identifying the cybercriminal, support vector machine (SVM) in the C SVM classification and K -nearest neighbor (KNN) models is utilized for determining the cybercrime information. The evaluation of the performance is done taking the following metrics into consideration: true positive, false positive, true negative and false negative, false alarm rate, detection rate, accuracy, recall, precision, specificity, sensitivity, classification rate, and Fowlkes-Mallows Scores. Expectation maximization (EM) calculation is utilized for evaluating the presentation of the Gaussian mixture model. The performance of classifier's presentation is also done. Accuracy is accomplished in the event of grouping by means of SVM classifier as 89% in the supervised method. [ABSTRACT FROM AUTHOR]

Research has been conducted on the cholesterol release to beta-cyclodextrin from mixtures with phospholipids. The measurements for the release rate constants are presented.

The new approach to develop quality in pharmaceuticals is by implementing Quality by Design (QbD). It explains the use of Quality by Design to guarantee pharmaceutical quality. In this review, the QbD is described and some of its components are specified. Even though the Quality can be checked on products, integrating within the design will be more effective. The quality by design is based on the ICH guidelines and USP also requires compendial product consistency evaluation checks on the market. As far as industry is concern - it is improving the quality and safety of their products by application of DoE using various software, since the cost of each software is higher, choosing the best software which has easy user interface as well as more performance is concerned. These QbD is implemented with creating DoE in the statistical application of production data with the help of various commercially available software (JMP®, MODDE®, MINITAB®, STATISTICA®, etc.,). The potential power of each software is unique and their functionalities are reviewed in this article. And it also gives you a brief idea about the software towards advancement in pharmaceutical sector in term of quality and safety. [ABSTRACT FROM AUTHOR]

Nanotechnology is a multidisciplinary d0omain which has provoked a significant impact on clinical medicine. Throughout the years nanotechnology has evolved in various aspects rendering multiple applications in the field of pharmaceutical development and overcoming the problems of conventional techniques. Nanotechnology has already acquainted with oncology facilitating the treatment of tumours. Nanotechnology posses various characteristics like preferential accumulation of chemotherapeutics in tumour, low distribution in normal tissues, pharmacokinetics, biodistribution and clearanceproviding improved diagnosis and tumour treatment. Though the field of oncology developed massively, limitations still exists in treating neuronal tumours due to intricate structure of the blood-brain barrier. Nanotechnology with its feasibility to attachvarious molecules on their surface and transform them into excellent transport vehicles with ability to cross cell and/or tissue barriers, including the BBB. This review elaborately delivers the techniques and strategies used to improve the diagnosis and to treat neuronal tumours unlike conventional cancer therapies. [ABSTRACT FROM AUTHOR]

Personalized medicine is a clinical model that isolates individuals into various groups with clinical choices, practices, intercessions and additionally items being customized to the individual patient dependent on their anticipated reaction or danger of disease. The utilization of genetic data has assumed a significant part in personalized medicine (e g pharmacogenomics). Modern advances in personalized medicine depend on innovation that affirms a patient's major DNA, RNA, biology or protein, which at last prompts confirming disease. The ideas of personalized medication can be applied to new and extraordinary ways to deal with medical services. The history of personalized medicine is clearly discussed in this article. And with that, literature review on various type of clinical trial was done. The two types of clinical trials are conventional clinical trial and differential clinical trial. The conventional clinical trial is a regular trial in which simple drugs are evaluated and the study can be done by observing all the phases. But in the case of differential clinical trial, the clinical trial is been carried out on complicated diseases and personalized medicines, where there are no proper regulatory guidelines to be followed. It is concluded that the advancing field of personalized medication is an emerging zone with a range of applications for rare diseases, which include actual advances in clinical trial outcomes for properly chosen patient sub-sets. [ABSTRACT FROM AUTHOR]

At present, In the pharmaceutical industry, the quality by design approach is widely used to obtain products with reliability and efficacy. Quality by design allows us to understand both product and process control through clear research and quality risk management. As QbD helps in building quality in all pharmaceutical products, it widely practised. But it may also be a drawback for few industries in which processes are fixed in time. It is one of the growing area which helps maintaining high quality standards and real time release of the drug product. To deliver a product performing its intended action by maintaining its quality, is the prime aim of pharmaceutical development. Implementation of QbD is widely encouraged by Food and Drug Administration (FDA) and International Conference on Harmonization (ICH). This study explored the pharmaceutical QbD and discusses how it can be used within the specified time frame to produce pharmaceutical products efficiently. In this review, a brief overview about QbD and its elements such as quality target product profile (QTPP) critical quality attributes (CQAs), Quality Risk management (QRM), Control strategy and continual improvement will be discussed. Moreover, an overview about water as a QbD element was also discussed. Understanding the concepts of QbD is essential as most of the pharmaceutical industry are moving towards implementing QbD in their area. So, QbD will act as a bridge between drug application review and risk-based drug development. [ABSTRACT FROM AUTHOR]